AIMS/HYPOTHESIS: The enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) modulates tissue-specific glucocorticoid concentrations by generating active cortisol. We have shown that adipose tissue 11beta-HSD1 mRNA levels were associated with adiposity and insulinaemia. Here we conducted further expression and genetic association studies in Pima Indians. METHODS: The 11beta-HSD1 mRNA concentrations were measured in abdominal subcutaneous adipocytes (n=61) and skeletal muscle tissues (n=64). Single nucleotide polymorphisms in the HSD11B1 gene were genotyped in a larger group of full-blooded Pima Indians. RESULTS: Two representative SNPs (SNP1, n=706; SNP5, n=839) were associated with Type 2 diabetes mellitus (p=0.01), although neither SNP was associated with obesity. Among subjects with normal glucose tolerance, SNP1 (n=127) and SNP5 (n=159) were associated with insulin-mediated glucose uptake rates (p=0.03 and p=0.04), and SNP1 was further associated with fasting, 30-min, and 2-h plasma insulin concentrations (p=0.002, p=0.002 and p=0.03). Adipocyte 11beta-HSD1 mRNA concentrations were correlated positively with adiposity and insulinaemia, and were additionally negatively correlated with insulin-mediated glucose uptake rates; nevertheless, the adipocyte 11beta-HSD1 expression did not correlate with genotypes of the donors. The muscle 11beta-HSD1 mRNA concentrations did not correlate with any anthropometric or metabolic variables. CONCLUSIONS/ INTERPRETATION: We confirmed that adipocyte 11beta-HSD1 mRNA concentrations were associated with adiposity, and showed that genetic variations in the HSD11B1 gene were associated with Type 2 diabetes mellitus, plasma insulin concentrations and insulin action, independent of obesity. The variable adipose expression might not be a primary consequence of these HSD11B1 SNPs. Therefore, it is possible that the HSD11B1 gene is under tissue-specific regulation, and has tissue-specific consequences.
AIMS/HYPOTHESIS: The enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) modulates tissue-specific glucocorticoid concentrations by generating active cortisol. We have shown that adipose tissue 11beta-HSD1 mRNA levels were associated with adiposity and insulinaemia. Here we conducted further expression and genetic association studies in Pima Indians. METHODS: The 11beta-HSD1 mRNA concentrations were measured in abdominal subcutaneous adipocytes (n=61) and skeletal muscle tissues (n=64). Single nucleotide polymorphisms in the HSD11B1 gene were genotyped in a larger group of full-blooded Pima Indians. RESULTS: Two representative SNPs (SNP1, n=706; SNP5, n=839) were associated with Type 2 diabetes mellitus (p=0.01), although neither SNP was associated with obesity. Among subjects with normal glucose tolerance, SNP1 (n=127) and SNP5 (n=159) were associated with insulin-mediated glucose uptake rates (p=0.03 and p=0.04), and SNP1 was further associated with fasting, 30-min, and 2-h plasma insulin concentrations (p=0.002, p=0.002 and p=0.03). Adipocyte 11beta-HSD1 mRNA concentrations were correlated positively with adiposity and insulinaemia, and were additionally negatively correlated with insulin-mediated glucose uptake rates; nevertheless, the adipocyte 11beta-HSD1 expression did not correlate with genotypes of the donors. The muscle 11beta-HSD1 mRNA concentrations did not correlate with any anthropometric or metabolic variables. CONCLUSIONS/ INTERPRETATION: We confirmed that adipocyte 11beta-HSD1 mRNA concentrations were associated with adiposity, and showed that genetic variations in the HSD11B1 gene were associated with Type 2 diabetes mellitus, plasma insulin concentrations and insulin action, independent of obesity. The variable adipose expression might not be a primary consequence of these HSD11B1 SNPs. Therefore, it is possible that the HSD11B1 gene is under tissue-specific regulation, and has tissue-specific consequences.
Authors: Robert C Andrews; Olive Herlihy; Dawn E W Livingstone; Ruth Andrew; Brian R Walker Journal: J Clin Endocrinol Metab Date: 2002-12 Impact factor: 5.958
Authors: B Davani; A Khan; M Hult; E Mårtensson; S Okret; S Efendic; H Jörnvall; U C Oppermann Journal: J Biol Chem Date: 2000-11-10 Impact factor: 5.157
Authors: Jukka Westerbacka; Hannele Yki-Järvinen; Satu Vehkavaara; Anna-Maija Häkkinen; Ruth Andrew; Deborah J Wake; Jonathan R Seckl; Brian R Walker Journal: J Clin Endocrinol Metab Date: 2003-10 Impact factor: 5.958
Authors: Eva Rask; Brian R Walker; Stefan Söderberg; Dawn E W Livingstone; Mats Eliasson; Owe Johnson; Ruth Andrew; Tommy Olsson Journal: J Clin Endocrinol Metab Date: 2002-07 Impact factor: 5.958
Authors: Robert S Lindsay; Deborah J Wake; Saraswathy Nair; Joy Bunt; Dawn E W Livingstone; Paska A Permana; P Antonio Tataranni; Brian R Walker Journal: J Clin Endocrinol Metab Date: 2003-06 Impact factor: 5.958
Authors: Laurence Duplomb; Young Lee; May-Yun Wang; Byung H Park; Kiyosumi Takaishi; Anil K Agarwal; Roger H Unger Journal: Biochem Biophys Res Commun Date: 2004-01-16 Impact factor: 3.575
Authors: Elise L V Malavasi; Val Kelly; Nikita Nath; Alessandra Gambineri; Rachel S Dakin; Uberto Pagotto; Renato Pasquali; Brian R Walker; Karen E Chapman Journal: Endocrinology Date: 2009-11-24 Impact factor: 4.736
Authors: Juan C Lopez-Alvarenga; Sven O E Ebbesson; Lars O E Ebbesson; M Elizabeth Tejero; V Saroja Voruganti; Anthony G Comuzzie Journal: Metabolism Date: 2009-09-18 Impact factor: 8.694